<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477008</url>
  </required_header>
  <id_info>
    <org_study_id>CR09-006</org_study_id>
    <secondary_id>9907776</secondary_id>
    <nct_id>NCT01477008</nct_id>
  </id_info>
  <brief_title>BiPhasic Cartilage Repair Implant (BiCRI) IDE Clinical Trial - Taiwan</brief_title>
  <official_title>A Prospective, Multi-Center, Randomized Clinical Trial Comparing the Biphasic Cartilage Repair Implant to Marrow Stimulation in the Treatment of Focal Chondral and Osteochondral Lesions of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioGend Therapeutics Co.Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioGend Therapeutics Co.Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and effectiveness of the Biphasic&#xD;
      Cartilage Repair Implant (BiCRI) compared to marrow stimulation in the treatment of chondral&#xD;
      and osteochondral lesions located on the medial femoral condyle, lateral femoral condyle, or&#xD;
      trochlea of the knee. The hypothesis is that the BiCRI provides an improvement in pain and&#xD;
      function as compared to baseline, that is no worse than marrow stimulation at 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IKDC-2000 Subjective Knee Evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Subjective evaluation of knee pain and function (will be captured at preop and each postop visit through 12 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IKDC-2000 Knee Examination Form</measure>
    <time_frame>Preop, 6 weeks, 3 months, 6 months, and 12 months</time_frame>
    <description>Objective evaluation of knee pain and function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC-2000 Current Health Assessment Form</measure>
    <time_frame>Preop, 6 weeks, 3 months, 6 months, and 12 months</time_frame>
    <description>Subjective evaluation of quality of life (QOL) and activities of daily living (ADL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>Preop, 6 weeks, 3 months, 6 months, and 12 months</time_frame>
    <description>A subjective instrument to assess the subject's opinion about their knee and associated problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (VAS): sitting, standing, and squatting</measure>
    <time_frame>Preop, 6 weeks, 3 months, 6 months, and 12 months</time_frame>
    <description>Subjective evaluation of pain during routine activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imagining (MRI)</measure>
    <time_frame>Preop and 12 months</time_frame>
    <description>MRI to evaluate cartilage and bone condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographs</measure>
    <time_frame>Preop, immediate postop, 6 weeks, 3 months, 6 months, 12 months</time_frame>
    <description>Not all views taken at each time frame.&#xD;
Weight bearing full extension AP view (both knees)&#xD;
Rosenberg view (45 degree PA flexion weight bearing, both knees)&#xD;
Lateral view of involved knee&#xD;
Sunrise (skyline) view of involved knee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Treatment through 12 months</time_frame>
    <description>Documentation of all adverse events from treatment through the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arthroscopy with biopsy</measure>
    <time_frame>12 months</time_frame>
    <description>Arthroscopic second look to visualize the repair site. Biopsy of the cartilage and bone region of the treated site. Only performed on patients who agree to second procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Chondral or Osteochondral Lesion of Medial Femoral Condyle</condition>
  <condition>Chondral or Osteochondral Lesion of Lateral Femoral Condyle</condition>
  <condition>Chondral or Osteochondral Lesion of Trochlea</condition>
  <arm_group>
    <arm_group_label>BiCRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BiPhasic Cartilage Repair Implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marrow Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microfracture or Subchondral Drilling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiPhasic Cartilage Repair Implant</intervention_name>
    <description>1 or 2 BiCRI devices, depending on lesion size</description>
    <arm_group_label>BiCRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Marrow Stimulation</intervention_name>
    <description>Microfracture or Subchondral Drilling</description>
    <arm_group_label>Marrow Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male or female presenting with a single, symptomatic chondral or osteochondral lesion&#xD;
             of the medial or lateral femoral condyles or the trochlea requiring primary surgical&#xD;
             intervention&#xD;
&#xD;
          2. Skeletally mature (epiphyses are confirmed to be closed on x-ray)&#xD;
&#xD;
          3. ICRS grade 3-4 lesion, Outerbridge grade 4, or OCD grades 3-4&#xD;
&#xD;
          4. Lesion size requires no more than 2 implants (assuming patient were to be randomized&#xD;
             to the treatment group). Lesion size will be assessed at the time of the study&#xD;
             procedure for all subjects. If the size of the lesion is appropriate for 1 or 2&#xD;
             implants the patient will be randomized. If the lesion is found to be too large the&#xD;
             patient will not be included in the trial, but will be treated according to standard&#xD;
             of care. Lesion sizes that are considered appropriate include the following:&#xD;
&#xD;
               -  Lesion is 3mm x 3mm or larger and can be completely covered by the small (12.5mm&#xD;
                  diameter) sizer (excluding small fissures). This lesion should be treated with 1&#xD;
                  implant. or&#xD;
&#xD;
               -  Lesion is 3mm x 3mm or larger and cannot be covered by the small sizer, but can&#xD;
                  be completely covered by the large (oval shaped) sizer (excluding small&#xD;
                  fissures). This lesion should be treated with 2 implants.&#xD;
&#xD;
          5. Willing and able to refrain from taking pain medications (including: narcotic and&#xD;
             non-steroidal anti-inflammatory drugs) for 7 days prior to the baseline preoperative&#xD;
             visit and for 7 days prior to the 12-month postoperative visit (i.e., a &quot;wash out&quot;&#xD;
             period)&#xD;
&#xD;
          6. Willing and able to return for follow-up over a one year post-operative period&#xD;
&#xD;
          7. Willing and able to comply with all postoperative guidelines&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. ≥ 55 years old&#xD;
&#xD;
          2. Lesions &gt; grade II on the articular surface of the tibia or patella&#xD;
&#xD;
          3. Kissing lesions (defined as an opposing lesion &gt; grade II on the surface of the tibia&#xD;
             or patella). Lesion ≤ grade II on opposing surface would be acceptable.&#xD;
&#xD;
          4. Prior surgical treatment of the lesion&#xD;
&#xD;
          5. Lesion would require more than 2 implants (assuming patient were to be randomized to&#xD;
             the treatment group). Lesion sizes that are not considered appropriate include the&#xD;
             following:&#xD;
&#xD;
               -  Lesion is smaller than 3mm x 3mm&#xD;
&#xD;
               -  Lesion cannot be completely covered by the large sizer&#xD;
&#xD;
          6. Lesion will require bone grafting&#xD;
&#xD;
          7. Rheumatoid arthritis and other inflammatory arthritis&#xD;
&#xD;
          8. Concomitant comorbidities, such as:&#xD;
&#xD;
               -  ACL instability that will not be corrected before or during the study procedure&#xD;
                  (&quot;ACL instability&quot; defined as the presence of a positive &quot;pivot shift&quot; test)&#xD;
&#xD;
               -  Significant knee instability that will not be corrected before or during the&#xD;
                  study procedure&#xD;
&#xD;
               -  Significant malalignment (varus or valgus deformity, patellar malalignment) that&#xD;
                  will not be corrected before or during the study procedure. Significant&#xD;
                  malalignment defined as:&#xD;
&#xD;
                    -  Any joint space narrowing as compared to the same compartment in the&#xD;
                       contralateral knee.&#xD;
&#xD;
                    -  Mechanical axis alignment outside the tibial spines.&#xD;
&#xD;
                    -  Patellofemoral subluxation on sunrise view.&#xD;
&#xD;
                    -  History of patellar dislocation or subluxation.&#xD;
&#xD;
               -  Severe meniscal damage (&quot;Severe meniscal damage&quot; defined as &gt; 50% of the meniscus&#xD;
                  missing or a radial tear extending to the meniscal-synovial junction)&#xD;
&#xD;
               -  Knee stiffness, defined as:&#xD;
&#xD;
                    -  Flexion contracture &gt;10°&#xD;
&#xD;
                    -  Flexion degree &lt; 115°&#xD;
&#xD;
          9. Body Mass Index (BMI) &gt; 35.0&#xD;
&#xD;
         10. Local or systemic infection, not including asymptomatic urinary tract infection if&#xD;
             treated with antibiotics preoperatively&#xD;
&#xD;
         11. Pregnancy or breast feeding&#xD;
&#xD;
         12. Prisoner&#xD;
&#xD;
         13. Patient is involved in a personal litigation (e.g. Worker's Compensation lawsuit) that&#xD;
             relates to their knee surgery&#xD;
&#xD;
         14. Patient is actively participating in another medical device, drug, or biologic&#xD;
             investigation (active defined as within the last 30 days)&#xD;
&#xD;
         15. Patient otherwise meets the study criteria but refuses to consent in writing to&#xD;
             participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Chen, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>BioGend Therapeutics Co.Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang Ho Hospital</name>
      <address>
        <city>Taipei county</city>
        <state>Taipei</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Show Chwan Memorial Hospital (SCMH)</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Kaohsiung (CGMH-KS)</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital Linkou (CGMH-LK)</name>
      <address>
        <city>Linkou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital (CMUH)</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital Taichung (VGHTC)</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Medical Center (NCKUMC)</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital (NTUH)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shuang Ho Hospital (SHH)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Tzu Chi Hospital (TTCH)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital (TSGH)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee</keyword>
  <keyword>Cartilage repair</keyword>
  <keyword>Cartilage regeneration</keyword>
  <keyword>Chondral</keyword>
  <keyword>Osteochondral</keyword>
  <keyword>Biphasic scaffold</keyword>
  <keyword>Medical device</keyword>
  <keyword>Autologous</keyword>
  <keyword>Synthetic</keyword>
  <keyword>Medial condyle</keyword>
  <keyword>Lateral condyle</keyword>
  <keyword>Trochlea</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

